Curaleaf's European Cannabis Empire: Inside the $47M International Push

Curaleaf Is Building a Cannabis Empire Across the Atlantic

While most American cannabis companies have spent 2026 battling price compression, regulatory uncertainty, and shrinking margins at home, Curaleaf Holdings has been quietly executing a different playbook: going international. The results are showing up on the balance sheet.

In its first quarter 2026 earnings, Curaleaf reported international revenue of $47.2 million, up 35% year-over-year. The company posted net income of $70 million—a sharp contrast to the net losses that have characterized the cannabis sector for most of its public-market existence. Total revenue hit a robust pace, with international operations now representing a meaningful and growing share of the business.

The centerpiece of this strategy has a name: Four 20 Pharma.

The Four 20 Pharma Story

On April 30, 2026, Curaleaf completed its buyout of the remaining 45% stake in Four 20 Pharma, a German medical cannabis producer and distributor. The acquisition gave Curaleaf full ownership of an EU-GMP and GDP certified operation that has become its European anchor.

Four 20 Pharma isn't a startup. It's an established player in Germany's medical cannabis market, holding the pharmaceutical licenses and quality certifications that are essential for operating in the EU's heavily regulated environment. EU-GMP (Good Manufacturing Practice) and GDP (Good Distribution Practice) certifications represent years of investment in facilities, processes, and documentation—barriers to entry that protect established operators from quick competition.

The full acquisition consolidates Curaleaf's control over its European supply chain, from cultivation through distribution to patients. Rather than licensing products through third parties, the company can now manage every link in the chain directly.

Why Germany Matters

Germany isn't just another European cannabis market. It's the largest medicinal cannabis import market on the continent, and its regulatory trajectory makes it a bellwether for the rest of Europe.

In 2024, Germany removed cannabis from the Narcotics Act (Betäubungsmittelgesetz, or BtMG), streamlining prescription pathways while maintaining pharmaceutical oversight. The reform didn't create a recreational free-for-all—instead, it made medical cannabis more accessible through existing healthcare channels, with health insurance potentially covering prescriptions for qualifying patients.

This balance between access and regulatory discipline has attracted serious capital. For a company like Curaleaf, Germany's approach offers something the American market can't: a regulated pharmaceutical framework where cannabis products are treated as medicine, not just retail goods. That means less price pressure from commoditization, better margins, and a more stable regulatory environment.

Germany's population of 84 million and its position at the center of the EU economy make it a natural base for broader European expansion. A company that establishes manufacturing and distribution infrastructure in Germany can reach neighboring markets with relatively modest additional investment.

Expanding Beyond Germany

Curaleaf isn't stopping at the German border. Building on Four 20 Pharma's success, the company has launched the Four 20 brand in the United Kingdom and Poland, with additional international markets in the pipeline.

Each market presents different regulatory environments and opportunities. The UK's medical cannabis market has been growing steadily, with an increasing number of private clinics prescribing cannabis-based medicines. Poland, meanwhile, represents an emerging market with significant growth potential as its medical cannabis program matures.

The strategy of using a single branded platform—Four 20 Pharma—across multiple markets creates operational efficiencies and brand recognition. It also allows Curaleaf to apply lessons learned in Germany's demanding regulatory environment to new markets, where the compliance expertise becomes a competitive advantage rather than just a cost.

The Financial Case for Going International

Curaleaf's international push isn't altruistic—it's driven by cold financial logic.

The American cannabis market, while large, is brutal. Active cannabis business licenses in the U.S. declined to 37,555 in the most recent quarter, down roughly 13% over two years. Price compression has forced widespread discounting. Cannabis retailers have relied heavily on promotions and markdowns to move product, eroding margins across the board.

International markets, by contrast, operate under pharmaceutical pricing models that support healthier margins. Medical cannabis in Europe typically commands premium prices, and the regulatory barriers that make market entry difficult also protect incumbent operators from the kind of cutthroat competition that has devastated American cannabis profits.

Curaleaf's international division reported €172.5 million in revenue for full-year 2025, a 63% increase over 2024. The division is now operating at an annualized rate exceeding €200 million. These aren't marginal numbers—they represent a genuine second growth engine.

How This Reshapes the Industry

Curaleaf's European expansion carries implications beyond its own balance sheet.

First, it demonstrates that cannabis multistate operators can successfully transition to multinational operators. The skills required—regulatory navigation, supply chain management, brand building—translate across borders, even if the specific regulations differ.

Second, it puts pressure on other large American cannabis companies to develop international strategies. Companies that remain U.S.-only risk being left behind as global cannabis markets mature and consolidate.

Third, it highlights the divergence between American and European approaches to cannabis regulation. The European pharmaceutical model, for all its bureaucratic complexity, produces a more orderly market with better margins and more predictable outcomes. As the U.S. rescheduling process evolves, some American companies and regulators may look to European models for guidance.

Risks and Challenges

The international strategy isn't without risks. Regulatory changes in any country could affect operations. Currency fluctuations create financial exposure. And managing operations across multiple countries with different legal systems, languages, and business cultures adds organizational complexity.

There's also the question of whether European markets will eventually liberalize toward recreational use, which could both expand the addressable market and introduce the same competitive pressures that have challenged U.S. operators.

For now, though, Curaleaf's bet on Europe appears to be paying off. In an industry where most companies are still searching for sustainable profitability, a $70 million quarterly profit makes a compelling argument.

Looking Ahead

The second half of 2026 will be telling for Curaleaf's international ambitions. Integration of the full Four 20 Pharma operation, expansion into new markets, and the potential impact of U.S. rescheduling on the company's domestic business will all shape the trajectory.

For the broader cannabis industry, Curaleaf's European playbook offers a roadmap—or at least a proof of concept—for building a genuinely international cannabis business. Whether others can replicate it remains to be seen.